Distinction of patients at a higher mortality risk beyond stage-only prognostication is an active area of cancer research. Preoperative neutrophil to lymphocyte ratio (NLR) correlates with survival outcomes in colorectal cancer. In this study, the predictive value of NLR in 2536 patients with respectable tumors was compared with the American Joint Committee on Cancer and Memorial Sloan Kettering Cancer Center models. NLR improved the prognostication of these staging systems. Background: We studied the role of peripheral neutrophil to lymphocyte ratio (NLR) on survival outcomes in colon and rectal cancer to determine if its inclusion improved prognostication within existing staging systems. Patients and Methods: Disease-free (DFS) and overall survival (OS) hazard ratios (HRs) of pretreatment NLR were calculated for 2536 patients with stage I to III colon or rectal cancer and adjusted for age, positive/total number of nodes, T stage, and grade. The association of NLR with clinicopathologic features and survival was evaluated and compared with the American Joint Committee on cancer (AJCC) TNM staging and Memorial Sloan Kettering Cancer Center (MSKCC) models. Results: High NLR was significantly associated with worse DFS (HR, 1.36; 95% confidence interval [CI], 1.08-1.70; P ¼ .009) and OS (HR, 1.65; 95% CI, 1.29-2.10; P < .0005) in all stages for patients with colon, but not rectal, cancer. High NLR was significantly associated with site-specific worse prognosis, which was stronger in the left versus right colon; an inverse relationship with grade was found. The impact of high NLR on DFS and OS occurred early, with the majority of deaths within 2 years following surgery. Adjusted HRs for 5-year and 2-year outcomes in colon cancer per each additional 2-unit increase in NLR were 1.15 (95% CI, 1.08-1.23) and 1.20 (95% CI, 1.10-1.30), respectively. The addition of NLR enhanced the prognostic utility of TNM (TNM alone vs. TNM þ NLR: concordance index, 0.60 vs. 0.68), and MSKCC (MSKCC alone vs. MSKCC þ NLR: concordance index, 0.71 vs. 0.73) models for colon cancer patients. Conclusion: NLR is an independent prognostic variable for nonmetastatic colon cancer that enhances existing clinical staging systems.
Introduction
In the United States, colorectal malignancy is the second leading cause of cancer-related mortality. 1 Prognostication mainly relies on the clinical and pathologic stage at diagnosis. An active area of research is targeted at how best to define the subset of patients who are at higher risk for recurrence and decreased survival beyond stageonly prognostication. This distinction is beneficial to patient management by optimizing current treatment options and surveillance strategies for early detection of recurrence. Several prognostic factors have been studied in patients with colorectal cancer (CRC). Age, gender, tumor site, grade, and number of involved lymph nodes have been shown to correlate with survival outcomes. 2 Genomic and molecular characteristics of the tumor such as microsatellite stability have also been linked to patient outcomes. 3, 4 In addition to conventional risk factors, elevation of inflammatory markers such as C-reactive protein or a combined index of peripheral neutrophil and lymphocyte counts (neutrophil to lymphocyte ratio, NLR) have been shown to correlate with the survival outcomes in a number of malignancies including cervical, lymphocytic infiltrate has been shown to have prognostic value in CRC and is associated with favorable outcomes. This observation has led to development of a predictive tool called Immunoscore. 10, 11 This score has been validated in a worldwide consortium-based analysis of 1336 patients and has shown that time to recurrence in curable stage colon cancer was significantly longer in patients with a high Immunoscore. 12 It has been proposed that systemic inflammatory response to tumors is manifested in the peripheral white blood cells, such as neutrophils and lymphocytes. NLR was determined to be an independent prognostic factor for recurrence and mortality in a cohort of 372 patients with histologically proven stage II and III colon cancer. 13 These findings were confirmed in another study of 276 patients with node-negative colon cancer who underwent surgery, which showed that preoperative NLR strongly correlates with postoperative recurrence rates. 14 However, incorporating NLR as a prognostic marker has not been integrated into any of the accepted predictive models. The American Joint Commission on Cancer (AJCC) bases prognostication on overall tumor stage, including the depth of cancer penetration into or through the colon wall, the presence and number of lymph nodes affected, and the metastatic spread of cancer to distant organs. These guidelines are the most widely accepted and clinically used means for determining a patient's likelihood for surviving cancer. The stage of the tumor is also used to guide recommendations for the need for and type of chemotherapy. In addition, a number of other tumor markers with prognosticative implications have been assessed by pathologists. Signs of early metastasis such as lymphovascular and perineural invasion have been proposed to be used in clinical practice to direct targeted chemotherapy and immunotherapy. 15 Other prognostication models that focus upon clinically available data have shown promise for improving accuracy of determining a patient's diseasefree survival (DFS) and overall survival (OS). For instance, the Memorial Sloan Kettering Cancer Center (MSKCC) algorithm for predicting OS for patients with surgically resected colon cancer improved the concordance index (C-index)-the ability to correctly determine a patient's survival-from 0.60 using the AJCC criteria to 0.68 using a combination of factors such as T stage, age, gender, grade, number of examined lymph nodes, and number of positive nodes. 16 In this study, we sought to determine whether NLR in peripheral blood of patients with colon and rectal cancers correlates with survival outcomes, and if so, assess its ability to enhance the accuracy of the AJCC CRC screening guidelines and the MSKCC model in these patients.
Methods

Study Cohort and Determination of NLR Cut-off
The institutional review board of the Mayo Clinic (Rochester, MN) reviewed and approved this protocol. Patients with a diagnosis of stage I, II, or III colon or rectal cancer who underwent tumor resection with curative intent from 2004 to 2015 were identified through the Mayo Clinic Tumor Registry, which prospectively collects clinical, histopathologic, therapeutic, and outcome data. A standard protocol is followed, which includes annual follow-up until the patient is deceased unless requested otherwise by the patient or administration. The primary means of follow-up is the in-person visit with the providers at the Mayo Clinic (Rochester, MN).
Data regarding tumor stage, pathology, number of total lymph nodes examined, positive lymph nodes, and survival outcomes were obtained from the tumor registry and the electronic medical record. The absolute neutrophil and lymphocyte counts were obtained from the sample collected within 30 days prior to the tumor resection or any treatment, whichever came first. NLR was obtained by dividing absolute neutrophil to lymphocyte count. In cases in which tumor testing had been performed as part of clinical care, mismatch repair (MMR) status was determined by immunohistochemistry (IHC) for MLH1, MSH2, MSH6, and PMS2 proteins. A tumor was categorized as mismatch repair-deficient (dMMR) if there was absence of expression of one or more of these immunostains in the tumor and mismatch repair-proficient (pMMR) if expression of all stains were present.
Patients were required to have a biopsy-proven diagnosis of colon or rectal cancer along with clinical, radiographic, and pathologic assessments for staging purposes. Patients with stage IV CRCs were excluded from the analysis. Patients without preoperative or pretreatment complete blood count accessible in the electronic medical record within 30 days before the intervention were removed from the study. All the participating subjects had given authorization for research.
The R package survival receiver operating characteristic (version 1.0.3) 17 was used for statistical analysis. The point on the receiver operating characteristic curve with the largest sum of sensitivity and specificity was chosen as the best prognostic cutoff point for dichotomizing NLR. A cut-off value of 3.0 was noted to provide the optimum predictability of death (see Supplemental Figure 1 in the online version). The C-index was the primary measure for evaluating the performance of the Cox model. The C-indices were calculated for our cases of colon and rectal cancer using the AJCC CRC staging guidelines as well as the MSKCC model and were compared with the C-indices obtained with addition of NLR to these models. Analysis of variance was used to test the significance of the difference in the C-index between the 2 Cox models. To validate these findings, we have also run 500 permutations in patients with colon cancer by randomly shuffling the survival time and outcome. We generated a sampling distribution of the area under the curve (AUC) when the null hypothesis is true (NLR has no prediction power on survival outcome). We have shown that the actual AUC (0.598) is significantly higher (P < .0001) than the average AUC from permutations. 18 To test the robustness of the model, the data was split into training (2/3) and testing (1/3) datasets. The partial coefficients fitted in the training dataset were applied to the testing dataset to calculated predicted log hazards ratio (HR), which was then used to calculate the C-index.
Survival Analysis and Nomogram Development
The histogram for each continuous variable was manually reviewed to identify outliers, and extreme values were doublechecked in the data source for possible correction, or otherwise dropped from the analysis. After the basic data cleaning, we analyzed the demographics and tumor characteristics of the patients. Data were presented as mean, median, standard deviation, range, and percentages when appropriate.
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NLR and Colon Cancer Survival
We split the cohort according to the optimum discriminative cutoff for NLR. The Kaplan-Meier curve for 5-year OS was utilized to illustrate the correlation of the dichotomized NLR with survival outcomes. Univariate and multivariate survival analyses were conducted by fitting Cox proportional hazards models. The models estimated the association of variables, including NLR, gender, age at diagnosis, positive nodes, number of nodes examined, tumor T stage, and grade with respect to survival outcomes. OS was defined as the time in months from the date of diagnosis to death from any causes, and DFS was defined as the time from cancer diagnosis until recurrence of tumor or death from any cause. 19 Each continuous variable was checked for linearity assumption while controlling for confounding factors, and the results were visualized as partial coefficients over the whole range of corresponding variables. Depending on the data sparsity and confidence interval (CI) of the partial coefficients; NLR, age, and number of positive nodes were capped at 20, 30, and 40 respectively, as no additional effects beyond the corresponding cutoff points were observed. All of the variables were checked for constant proportional hazard ratio assumption, and the results were visualized as log hazard ratio over time. Although visualized results suggested a diminishing effect of NLR after 2 years, significance tests showed no violation of constant proportional hazard ratio assumption in the models. The log-rank test and likelihood ratio test were applied to calculate the probability of type I error. A P value of less than .05 was considered to be significant. The MSKCC model for predicting OS for patients with colon cancer utilized the Surveillance, Epidemiology, and End results (SEER) program of the National Cancer Institute as the source for development and testing of their nomogram. Because the raw data used to generate the MSKCC nomogram was not available to us, we utilized our data set to build the model that was proposed by this group. Nomograms were constructed using the methods described by Harrell. 20 
Results
A cohort of 2536 patients with stage I to III colon and rectal cancers (788 stage I, 787 stage II, and 961 stage III) and a median age of 67 years were included in the study (58.7% male). Of these, 1622 subjects had colon cancer, whereas 864 subjects had rectal cancer. The majority of tumors (59.1%) were poorly differentiated ( Table 1) .
The median NLR value was 2.95, with a range of 0 to 36.22 for colon and rectal cancers combined. A total of 1241 (49%) of subjects had an NLR of greater than 3, and were considered as the high NLR group, whereas the remaining 1295 (51%) were included in the low NLR group. Among patients with colon cancer, high NLR was associated with poor outcome for all stages combined and for each stage (Figure 1 ) but not for rectal cancer (see Supplemental Figure 2 in the online version). The adjusted HRs for 5-year and 2-year outcomes in colon cancer per each additional 2-unit increase in NLR were 1.15 (95% CI, 1.08-1.23) and 1.20 (95% CI, 1.10-1.30), respectively ( Table 2) . NLR HRs were not significant for rectal cancer (see Supplemental Table 1 in the online version). Data regarding adjuvant chemotherapy was available for a total of 410 stage II and 482 stage III cases of colon cancer. Among the patients with stage II disease and low NLR, 13.7% (n ¼ 27) received adjuvant chemotherapy compared with 38.9% (n ¼ 83) of those with high NLR (P < .001). For stage III colon cancer, however, the distribution of those who received adjuvant therapy is similar between the 2 groups (67.1% low NLR vs. 61.0% for high NLR; P ¼ .17).
When stratified by tumor location, the HR for high NLR remained significant for both right-and left-sided cancers of the colon, but not for the rectum (Figure 2 ). The poorer prognosis in patients with colon cancer with high versus low NLR was significantly higher for patients with left-sided rather than right-sided tumors. NLR inversely correlated with survival outcomes in both men and women (male HR, 1.34; 95% CI, 1.01-1.78 vs. female Abbreviations: NLR ¼ neutrophil to lymphocyte ratio; SD ¼ standard deviation.
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Clinical Colorectal Cancer June 2017 -117 HR, 1.62; 95% CI, 1.19-2.19). The association of both high NLR and HR among those with T3 lesions was significant; but this was not the case for any other T stages (Figure 2 ). When available, we also studied the association of NLR with respect to the MMR status of the cancer. We compared 442 patients (296 with colon cancer) with pMMR tumors with 114 (96 with colon cancer) patients with dMMR lesions. The difference (Figure 2) .
The association of high NLR with poor prognosis in colon cancer was linear for NLRs ranging from 0 to 15, but was less obvious beyond 15 to 20 ( Figure 3A) . The major impact of NLR on DFS and OS in these patients appeared to be an early event, primarily within the first 2 years of the diagnosis, as demonstrated by the constant proportional HR curve ( Figure 3B ). The predominant impact of NLR within the first 2 years post-diagnosis was primarily driven by stage III cases. The majority of patients who died in the first 2 years following surgery had a high versus low NLR (see Supplemental Figure 3 in the online version).
We studied the prognostic value of NLR as an addition to the AJCC staging/prognostic guideline commonly used in clinical practice. In our study, the addition of NLR significantly improved the prognostication for colon cancer (C-index 0.60 vs. 0.68; P < .0001), whereas it did not affect the prognostication for rectal cancer (see Supplemental Table 2 in the online version). Utilizing conventional prognostic markers proposed by the MSKCC model for colon cancer, we determined that the C-index of the model fitted in our dataset was 0.71 (95% CI, 0.68-0.74), and the addition of NLR improved its prognostic accuracy to 0.73 (95% CI, 0.70-0.76). When coefficients generated from the training dataset (2/3 of subjects) were applied to the testing dataset (1/3 of subjects), the concordance remained at 0.73 (95% CI, 0.67-0.79) for colon cancer. The associated nomogram with this model is shown in Figure 4 . With regard to rectal cancer, implementing NLR did not change the predictive performance of the model mortality risk (C-index ¼ 0.74; 95% CI, 0.68-0.80). When generated from the testing dataset, the fitted C-index in rectal cancer was 0.73 (95% CI, 0.63-0.84).
Discussion
In this study, we determine the impact of pretreatment NLR on mortality, which extends and refines the known negative effect of a high NLR on survival from colon and rectal cancer. [21] [22] [23] We have identified several clinical features, including the tumor's site, grade, and MMR status, that affect prognosis in a large group of patients with colon and rectal cancer with a high pretreatment NLR. The inverse correlation of NLR with DFS and OS is another important finding in this study. Interestingly enough, although a higher proportion of the patients with high NLR received adjuvant therapy compared with those with low NLR in stage II disease, they had worse outcomes. The difference in receiving adjuvant therapy was not significant for stage III cases of colon cancer. We report that the simple addition of NLR improves prognostication for colon cancer over that of the most routinely clinically used TNM staging system and the more precise, but less routinely used MSKCC model. Similar to other studies, we found that high NLR is associated with a poorer prognosis for patients with colon cancer. However, whereas others have reported a similar association for patients with rectal cancer, we did not. 23, 24 Applying the NLR cutoff of 3.0 that was discriminant for colon cancer to the patients with rectal cancer, NLR still did not correlate with DFS or OS in our patients with rectal cancer. Other factors, such as differences in the diagnostic work-up to identify the need for neoadjuvant treatment, use and 
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Clinical Colorectal Cancer June 2017 -119 expertise of total mesorectal dissection, or other features that may impact rectal cancer outcomes, may have made our group of patients with rectal cancer dissimilar to those in other studies. Additionally, rectal cancer is biologically distinct and treated differently from colon cancer; as such, the prognostic value of peridiagnostic NLR could be confounded by other factors such as rectal cancer-specific radiotherapy. Last, it is possible that, owing to a smaller number of patients with rectal cancer in our cohort, the study did not have the power to detect the impact of NLR on outcomes for patients with rectal cancer. In our study, the association of high NLR with worse outcomes for patients with colon cancer was limited to those with well-to moderately-but not poorly-differentiated tumors. In general, tumor grade has not been an effective prognostication feature for colorectal cancer, with the exception of some very specific histologic and molecular phenotypes. The prognosis for patients with CRC with signet ring histology is poor, whereas medullary histology, which is pathognomic for dMMR colon cancer, 25 is associated with better DFS and OS. We found that, for patients with a high NLR, those with leftsided colon cancer had a significantly poorer prognosis than patients with right-sided colon cancer. In other studies in which NLR was not determined, patients with right-sided colon cancers have higher cancer-specific mortality, which is driven by those tumors that are pMMR. MMR deficiency results in an increased mutation rate owing to microsatellite instability in the cancer genome. This hypermutability is recognized as a high cancer antigen burden that triggers a significant immune-response recently exploited with targeted immunotherapy to successfully treat both colonic and extracolonic dMMR cancer. 26 Histologically, dMMR tumors present with increased tumor-infiltrating lymphocytes that may reflect the immunogenicity of these highly mutated cancer cells. These patients have a better prognosis than patients with pMMR tumors. In our study, although the difference between HRs for patients with a high NLR and dMMR compared with cases of pMMR colon cancer did not reach statistical significance because of
Figure 4 OS and DFS Prediction Nomograms in Stage I to III Colon Cancer. Nomogram Utilizing Variables Utilized in the Memorial Sloan Kettering Cancer Center Predictive Model With the Addition of NLR for OS (A) and DFS (B). Implementing NLR in the Prognostic Model Improves the Predictive Accuracy of Outcomes in Stage I to III Colon Cancer
Abbreviations: DFS ¼ disease-free survival; NLR ¼ neutrophil to lymphocyte ratio; OS ¼ overall survival.
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Clinical Colorectal Cancer June 2017 -121 small sample size, it suggests that the host NLR response may overcome the prognostic benefit of dMMR tumors. Further study of the associations of NLR with tumor sidedness, grade, and particularly MMR status may provide the framework for more individualized prognostication. Although lymphocytic infiltration of tumors has been shown to be associated with promising outcomes in dMMR CRC, 10 the prognostic value of neutrophil infiltration has yet to be studied. On the other hand, neutrophilia is associated with worse outcomes in a number of cancers. 2, 27, 28 Intratumoral neutrophils have been connected with biologically aggressive disease. 29 The association of high NLR with poor outcome may be explained by tumor-induced neutrophilia and tumor infiltration of neutrophils. In addition to the prognostic implications of tumor-associated neutrophils, these entities are a potential therapeutic target in CRC. 30 Further studies to confirm the correlation of neutrophilic infiltration with NLR is warranted. We have shown that the OS and DFS HRs associated with NLR are higher in the first 2 years following the diagnosis of colon cancer. This observation is somewhat expected, as the majority of prognostic factors lose their predictive capability over time. The contribution of NLR to survival is also diluted over time as the impact of other factors such as aging or therapy become more dominant. Among those with elevated NLR, the mortality rate was higher within the first 2 years, and this may explain the early impact of NLR.
The association of NLR with mortality is not specific to cancer and can be seen in nonmalignant conditions. Nonetheless, persistent correlation of this marker with cancer-related outcomes suggests an underlying mechanism linking leukocytes to tumor biology that could be targeted for developing effective therapy. Just as MSI status, K-ras, 31 and BRAF 32 mutations are now accepted biomarkers that impact prognosis and/or treatment response, NLR has the potential to be utilized in chemotherapy-based clinical trials to determine the impact of the host immune system upon responsiveness to therapeutic agents as well as prognosis. The mortality risk of having a high NLR differed based on the tumor's grade, site, and MMR status, which suggests that there is an association between the clinical phenotype of the tumor and the patient's (host) response to the tumor. This could provide a metric of the general underlying fitness of the patient to tolerate the stress of cancer and the associated surgery and/or chemo/radiotherapy. NLR may reflect other life-limiting comorbid conditions that impact DFS and OS, such as underlying cardiac or kidney disease. 33 Though our study evaluates preoperative NLR as a prognostic indicator, serial NLR values, routinely collected during therapy, could monitor responsiveness to chemotherapy-related symptoms.
We report that pretreatment peripheral blood NLR carries an independent prognostic value in colon cancer when compared with well-established models. In this innovative approach, we compared the prognostic value of NLR with AJCC CRC and MSKCC prognostic models in patients with CRC. The simple addition of NLR improves prognostication for colon cancer over that of the most routinely clinically used AJCC model. Similarly, NLR is better able to predict the outcome of a patient with colon cancer than the MSKCC model, which, although a better predictor of outcome than the AJCC model, is not used in most clinical practices. Of note, our prognostication model differed from the MSKCC model, which included a pediatric population, whereas we only studied adults.
We have shown that NLR not only improves the performance of prognostication for colon cancer but also that the magnitude of NLR predictability for OS was higher than the pathologic grade of the colonic tumor in our model. The model generated for rectal cancer in our samples-utilizing the features in the MSKCC nomogram calculator-performed as well as our colon cancer model. 34 Our rectal cancer model put more weight on the prognostic significance of high-grade lesions and the total number of involved lymph nodes. The addition of NLR to this model did not improve prognostication for rectal cancer, nor was NLR alone prognosticative for rectal cancer. Overall, the findings of this study propose NLR as an inexpensive and readily available independent prognostic biomarker for colon cancer, which could be incorporated as simple addition into AJCC guidelines or alternatively to the existing publicly available MSKCC calculators.
Clinical Practice Points
Prognostication improves by addition of clinicopathologic factors to the current colorectal cancer staging systems. Preoperative NLR correlates with poor prognosis and recurrence rate in colorectal cancer. Preoperative NLR correlates with worse DFS and OS in patients with stage I to III colon cancer but not those with rectal cancer. High NLR was associated with location and grade of the tumor. The simple addition of the NLR improves the prognostication of the AJCC and MSKCC staging systems, which could better identify those with aggressive colon cancer and meaningfully impact clinical care. The adjusted HR for every 2-unit increase in NLR value is not significant for resectable rectal cancer within the first 2 and 5 years of diagnosis. Abbreviations: DFS ¼ disease-free survival; HR ¼ hazard ratio; NLR ¼ neutrophil to lymphocyte ratio; OS ¼ overall survival.
Supplemental Figure 3 Distribution of NLR According to the Endpoint in the First
Supplemental The addition of NLR to the AJCC criteria significantly improves the C-index in colon cancer from 0.60 to 0.68. For rectal cancer, the modest increase in C-index was not statistically significant. Abbreviations: AJCC ¼ American Joint Committee on Cancer; C-index ¼ concordance index; NLR ¼ neutrophil to lymphocyte ratio; SE ¼ standard error.
